What Future For Genentech's Lebrikizumab On Phase III Failure?
This article was originally published in Scrip
Roche/Genentech's IL-13 inhibiting investigational severe asthma product lebrikizumab has failed in one of its two pivotal trials, adding to reservations about its future. Lebrikizumab is already trailing other biological competitors to the market and the lack of robust data at Phase III could well spell the end in this indication.
Register for our free email digests: